Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.14
MDVN's Cash to Debt is ranked higher than
58% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. MDVN: 1.14 )
MDVN' s 10-Year Cash to Debt Range
Min: 1.1   Max: No Debt
Current: 1.14

Equity to Asset 0.21
MDVN's Equity to Asset is ranked higher than
51% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. MDVN: 0.21 )
MDVN' s 10-Year Equity to Asset Range
Min: -0.02   Max: 0.99
Current: 0.21

-0.02
0.99
F-Score: 4
Z-Score: 10.41
M-Score: -1.12
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -8.15
MDVN's Operating margin (%) is ranked higher than
78% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. MDVN: -8.15 )
MDVN' s 10-Year Operating margin (%) Range
Min: -510.27   Max: 66.67
Current: -8.15

-510.27
66.67
Net-margin (%) -15.61
MDVN's Net-margin (%) is ranked higher than
77% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. MDVN: -15.61 )
MDVN' s 10-Year Net-margin (%) Range
Min: -496.58   Max: 37.65
Current: -15.61

-496.58
37.65
ROE (%) -55.38
MDVN's ROE (%) is ranked higher than
61% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -20.60 vs. MDVN: -55.38 )
MDVN' s 10-Year ROE (%) Range
Min: -2940.27   Max: 4.99
Current: -55.38

-2940.27
4.99
ROA (%) -10.85
MDVN's ROA (%) is ranked higher than
76% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. MDVN: -10.85 )
MDVN' s 10-Year ROA (%) Range
Min: -73.93   Max: 4.69
Current: -10.85

-73.93
4.69
ROC (Joel Greenblatt) (%) -47.79
MDVN's ROC (Joel Greenblatt) (%) is ranked higher than
78% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. MDVN: -47.79 )
MDVN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -230657.14   Max: -47.79
Current: -47.79

-230657.14
-47.79
Revenue Growth (%) 58.60
MDVN's Revenue Growth (%) is ranked higher than
97% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. MDVN: 58.60 )
MDVN' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 60
Current: 58.6

0
60
EBITDA Growth (%) -19.00
MDVN's EBITDA Growth (%) is ranked higher than
67% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. MDVN: -19.00 )
MDVN' s 10-Year EBITDA Growth (%) Range
Min: -22.5   Max: 154.6
Current: -19

-22.5
154.6
EPS Growth (%) 4.50
MDVN's EPS Growth (%) is ranked higher than
85% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. MDVN: 4.50 )
MDVN' s 10-Year EPS Growth (%) Range
Min: 0   Max: 71
Current: 4.5

0
71
» MDVN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

MDVN Guru Trades in Q2 2013

Andreas Halvorsen 1,685,216 sh (+86.31%)
Steven Cohen Sold Out
Louis Moore Bacon Sold Out
» More
Q3 2013

MDVN Guru Trades in Q3 2013

Steven Cohen 1,900 sh (New)
Andreas Halvorsen Sold Out
» More
Q4 2013

MDVN Guru Trades in Q4 2013

Jim Simons 94,000 sh (New)
Steven Cohen 6,888 sh (+262.53%)
» More
Q1 2014

MDVN Guru Trades in Q1 2014

Mario Gabelli 15,046 sh (New)
John Burbank 3,173 sh (New)
Steven Cohen 216,962 sh (+3049.85%)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MDVN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2014-03-31 New Buy0.01%$61.08 - $86.97 $ 77.836%3173
Mario Gabelli 2014-03-31 New Buy0.01%$61.08 - $86.97 $ 77.836%15046
George Soros 2012-03-31 Sold Out 0.1%$45.84 - $75.56 $ 77.8329%0
George Soros 2011-12-31 New Buy0.1%$15.79 - $48.8 $ 77.83133%50000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Medivation Inc

Weekly CEO Sells Highlight: Vringo Inc, Medivation Inc, BioDelivery Sciences International Inc and HomeAway Inc.
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: Vringo Inc, Medivation Inc, BioDelivery Sciences International Inc, and HomeAway Inc. Read more...

Ratios

vs
industry
vs
history
P/B 72.60
MDVN's P/B is ranked higher than
56% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 5.51 vs. MDVN: 72.60 )
MDVN' s 10-Year P/B Range
Min: 0.59   Max: 1848.25
Current: 72.6

0.59
1848.25
P/S 18.10
MDVN's P/S is ranked higher than
73% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. MDVN: 18.10 )
MDVN' s 10-Year P/S Range
Min: 4.54   Max: 563.33
Current: 18.1

4.54
563.33
EV-to-EBIT -654.52
MDVN's EV-to-EBIT is ranked lower than
54% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MDVN: -654.52 )
MDVN' s 10-Year EV-to-EBIT Range
Min: 52.4   Max: 10203.9
Current: -654.52

52.4
10203.9
Current Ratio 3.87
MDVN's Current Ratio is ranked higher than
73% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. MDVN: 3.87 )
MDVN' s 10-Year Current Ratio Range
Min: 1.46   Max: 27.3
Current: 3.87

1.46
27.3
Quick Ratio 3.87
MDVN's Quick Ratio is ranked higher than
74% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. MDVN: 3.87 )
MDVN' s 10-Year Quick Ratio Range
Min: 1.46   Max: 27.3
Current: 3.87

1.46
27.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 72.70
MDVN's Price/Tangible Book is ranked higher than
60% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 8.78 vs. MDVN: 72.70 )
MDVN' s 10-Year Price/Tangible Book Range
Min: 0.3   Max: 1152.75
Current: 72.7

0.3
1152.75
Price/Median PS Value 0.60
MDVN's Price/Median PS Value is ranked higher than
94% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. MDVN: 0.60 )
MDVN' s 10-Year Price/Median PS Value Range
Min: 0.14   Max: 2.15
Current: 0.6

0.14
2.15
Forward Rate of Return (Yacktman) -3.24
MDVN's Forward Rate of Return (Yacktman) is ranked higher than
81% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: -10.54 vs. MDVN: -3.24 )
MDVN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 99.1   Max: 146.6
Current: -3.24

99.1
146.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:WMD.Germany
Medivation, Inc was formed in Delaware in October 1995. The Company is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Together with its collaboration partner Astellas Pharma Inc., or Astellas, the Company is developing XTANDI (enzalutamide) capsules. Together with Astellas, it is also conducting multiple trials of enzalutamide in earlier prostate cancer disease states, including the Phase 3 PREVAIL trial in patients with mCRPC who have not received chemotherapy, or pre-chemotherapy mCRPC patients, and in patients with breast cancer. Based on the positive results of the AFFIRM trial, the Company has exercised its right under its collaboration agreement with Astellas to co-promote XTANDI in the U.S., should it receive marketing approval. Their subsidiaries are Medivation Prostate Therapeutics, Inc., or MPT, Medivation Neurology, Inc., or MNI, Medivation Technologies, Inc., or MTI, Medivation Field Solutions, Inc., or MFSI, and Medivation Services, Inc., or MSI. MPT holds the intellectual property rights covering XTANDI. MNI holds the intellectual property rights covering dimebon, which previously was in development for Alzheimer's disease and Huntington disease under its former collaboration with Pfizer. MTI holds the intellectual property rights covering its early-stage technologies. MFSI provides commercialization services to the Company, and MSI provides research and development services. It has received "Fast Track" designation from the U.S. Food and Drug Administration, or FDA, for the post-docetaxel indication. The Company has obtained an exclusive, worldwide commercial license to a series of novel small molecules. The Company is conducting this program in collaboration with Astellas. Its business strategy is to use current GMP compliant contract manufacturers for manufacture of clinical supplies as well as for commercial supplies if required by its commercialization plans, and to transfer manufacturing responsibility to its collaboration partners when possible. The Company is subject to extensive regulation by the Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.
» More Articles for MDVN

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Vringo Inc, Medivation Inc, BioDelivery Sciences International Inc and H Feb 02 2014 
Andreas Halvorsen Buys 2 Million Shares of Medivation Aug 22 2012 
Weekly CFO Sells Highlight: SLCA, UNH, LVS, RATE, MDVN, YUM, TER Feb 14 2012 
Interview with CEO of Cellceutix Corporation: Leo Ehrlich Nov 15 2011 
Medivation Inc. (MDVN) Chief Business Officer and CFO Clarence Patrick Machado sells 16,800 Shares Feb 11 2011 
Medivation Inc. (MDVN) Chief Business Officer and CFO Clarence Patrick Machado sells 4,200 Shares Feb 08 2011 
Medivation Inc. (MDVN) Sr. Vice President and CFO Clarence Patrick Machado sells 10,000 Shares Jan 20 2010 
Medivation Inc. (MDVN) Sr. Vice President and CFO Clarence Patrick Machado sells 20,000 Shares Dec 08 2009 
Medivation Inc. (MDVN) President and CEO David Hung sells 25,000 Shares Dec 08 2009 
Medivation Inc. (MDVN) Sr. Vice President and CFO Clarence Patrick Machado sells 20,000 Shares Nov 13 2009 


More From Other Websites
Medivation Significantly Undervalued, With Xtandi Weeks Away From Prostate Cancer Label Expansion Jul 21 2014
Astellas Up on Pipeline Update, Oncology in Focus Jul 16 2014
Medivation Announces Change in Executive Management Team Jul 10 2014
Medivation Announces Change in Executive Management Team Jul 10 2014
Medivation Set To Go Higher As Prostate Cancer Drug Xtandi Quickly Approaches Blockbuster Status Jul 10 2014
3 Stocks Underperforming Today In The Health Care Sector Jul 03 2014
Aegis Capital Believes Seragon Deal Underscores Value In Medivation Jul 02 2014
MEDIVATION, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of... Jul 01 2014
Medivation Xtandi sales estimates raised at Citigroup Jun 25 2014
Stratasys, 3D Systems And Medivation Lead Small-Cap Bets For Back Half Of 2014 Jun 24 2014
UPDATE: Stifel Reiterates On Medivation Following Prostate Cancer Survey Jun 23 2014
Moving Average Crossover Alert: Medivation (MDVN) Jun 18 2014
Medivation Again Voted Among Top Workplaces in the SF Bay Area Jun 16 2014
Medivation Founder, President and Chief Executive Officer David Hung, M.D. Named an EY Entrepreneur... Jun 11 2014
Will Medivation (MDVN) Continue to Surge Higher? Jun 04 2014
Earnings Estimates Moving Higher for Medivation (MDVN): Time to Buy? Jun 04 2014
New England Journal of Medicine Publishes Results From Phase 3 PREVAIL Trial of Enzalutamide in Men... Jun 01 2014
New England Journal of Medicine Publishes Results from Phase 3 PREVAIL Trial of Enzalutamide in Men... Jun 01 2014
The Spectranetics (SPNC) Crumbles: Stock Falls by 8.1% May 29 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide